RandalK.WadaMD

Pediatric Hematology & Oncology • Honolulu, HI

Physician

Join to view full profile

Dr. Wada is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Wada's full profile

Already have an account?

Office
1319 Punahou St
Pediatric Ambulatory Unit
Honolulu, HI 96826
Phone+1 808-983-8551

Fax+1 808-983-8005
Is this information wrong?

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Pediatric Hematology/Oncology, 1986 - 1989
Children's Hospital Los AngelesResidency, Pediatrics, 1985 - 1986
Childrens Hospital Los AngelesInternship, Transitional Year, 1983 - 1984
Emory University School of MedicineClass of 1983

Certifications & Licensure

HI State Medical License 1996 - 2026
CA State Medical License 1985 - 2020
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma Start of enrollment: 2008 Jan 14
Completed
Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Roles: Contact, Principal Investigator
Preventative Trial of DFMO in Patients With High Risk Neuroblastoma in Remission Start of enrollment: 2012 Jun 01
Active, not recruiting
Phase 2
Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer Start of enrollment: 2013 Feb 01
Active, not recruiting
Not Applicable
Molecular-Guided Therapy for Childhood Cancer Start of enrollment: 2014 Jul 08
Completed
Not Applicable
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy Start of enrollment: 2015 Sep 01
Recruiting
Phase 2
Trial of Tolcapone With Oxaliplatin for Neuroblastoma Start of enrollment: 2015 Dec 01
Terminated
Phase 1
Neuroblastoma Maintenance Therapy Trial Start of enrollment: 2016 Feb 01
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.
Giselle L Saulnier Sholler, Genevieve Bergendahl, Elizabeth C Lewis, Jacqueline Kraveka, William Ferguson, Abhinav B Nagulapally, Karl Dykema, Valerie I Brown, Michael...> ;Genome Medicine. 2024 Feb 12
2 citations
Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.
Javier Oesterheld, William Ferguson, Jacqueline M Kraveka, Genevieve Bergendahl, Thomas Clinch, Elizabeth Lorenzi, Don Berry, Randal K Wada, Michael S Isakoff, Don E E...> ;Journal of Clinical Oncology. 2024 Jan 1
A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma.
Don Eslin, Peter E Zage, Genevieve Bergendahl, Elizabeth Lewis, William Roberts, Jacqueline Kraveka, Deanna Mitchell, Michael S Isakoff, Jawhar Rawwas, Randal K Wada, ...> ;International Journal of Cancer. 2023 Sep 1
3 citations
A pilot study of genomic-guided induction therapy followed by immunotherapy with difluoromethylornithine maintenance for high-risk neuroblastoma.
Jacqueline M Kraveka, Elizabeth C Lewis, Genevieve Bergendahl, William Ferguson, Javier Oesterheld, Elizabeth Kim, Abhinav B Nagulapally, Karl J Dykema, Valerie I Brow...> ;Cancer Reports. 2022 Nov 1
8 citations
Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion
Sara A. Byron, William P.D. Hendricks, Abhinav Nagulapally, Jacqueline M. Kraveka, William S. Ferguson, Valerie I. Brown, Don E Eslin, Deanna Mitchell, Albert Corneliu...> ;Cancer Research. 2021 Oct 5
A pediatric case of acute myeloid leukemia with KMT2A gene rearrangement t(10;11) and 16p11.2 microdeletion syndrome.
Keisuke Abe, Leah Dowsett, Randal K. Wada, Kelley K. Hutchins> ;Pediatric Blood & Cancer. 2021 Feb 1
Leadership, behavioral science, and interprofessional teamwork.
Randal K. Wada> ;Translational Behavioral Medicine. 2020 Oct 8
31 citations
A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma
Elizabeth C. Lewis, Jacqueline M. Kraveka, William S. Ferguson, Don Eslin, Valerie I. Brown, Genevieve Bergendahl, William Roberts, Randal K. Wada, Javier Oesterheld, ...> ;International Journal of Cancer. 2020 Dec 1
2 citations
Engaging a Community Chaplaincy Resource for Interprofessional Health Care Provider Training in Facilitating Family Decision Making for Children at End-of-Life.
Randal K. Wada, Lorrie Wong, Anke Flohr, David Kurahara, Robin Arndt, Melodee Deutsch, Dana Ing, Karol Richardson, Alexander Munro, Lori Kaneshige, Mary Mullis, Mychal...> ;Hawai'i Journal of Medicine & Public Health. 2019 Jun 1
58 citations
Maintenance DFMO Increases Survival in High Risk Neuroblastoma
Giselle Saulnier Sholler, William S. Ferguson, Genevieve Bergendahl, Jeffrey P. Bond, Kathleen A. Neville, Don Eslin, Valerie I. Brown, William Roberts, Randal K. Wada...> ;Scientific Reports. 2018 Sep 27
100 citations
A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma.
Giselle Saulnier Sholler, Eugene W. Gerner, Genevieve Bergendahl, Robert B. MacArthur, Alyssa VanderWerff, Takamaru Ashikaga, Jeffrey P. Bond, William S. Ferguson, Wil...> ;Plos One. 2015 May 27
7 citations
Hawai'i's multiethnic adolescent and young adult survivors of childhood cancer: are their health behavior risks similar to state and national samples?
Randal K. Wada, Darryl W. Glaser, Erin O'Carroll Bantum, Trina Orimoto, Alana Steffen, Jennifer Elia, Cheryl L. Albright> ;Hawai'i Journal of Medicine & Public Health. 2013 Nov 1
16 citations
PEA15 impairs cell migration and correlates with clinical features predicting good prognosis in neuroblastoma
Joanna E. Gawecka, Dirk Geerts, Jan Koster, Maisel J. Caliva, Florian J. Sulzmaier, John Opoku-Ansah, Randal K. Wada, André S. Bachmann, Joe W. Ramos> ;International Journal of Cancer. 2012 Oct 1
7 citations
Retinoic acid induced downregulation of MYCN is not mediated through changes in Sp1/Sp3.
Kelli K. Kanemaru, Matthew C. Tuthill, Kenneth K. Takeuchi, Neil Sidell, Randal K. Wada> ;Pediatric Blood & Cancer. 2008 Apr 1
34 citations
Na-K-2Cl cotransporter inhibition impairs human lung cellular proliferation
Lynn M. Iwamoto, Naomi Fujiwara, Kenneth T. Nakamura, Randal K. Wada> ;American Journal of Physiology. Lung Cellular and Molecular Physiology. 2004 Sep 1
86 citations
Assessment of optimal size and composition of the U.S. National Registry of hematopoietic stem cell donors.
Craig Kollman, Esteban Abella, Robert L. Baitty, Patrick G. Beatty, Ranajit Chakraborty, Cindy L. Christiansen, Robert J. Hartzman, Carolyn Katovich Hurley, Edgar L. M...> ;Transplantation. 2004 Jul 1
9 citations
Cord blood units collected at a remote site: A collaborative endeavor to collect umbilical cord blood through the Hawaii Cord Blood Bank and store the units at the Pug...
Randal K. Wada, Andrea Bradford, Margery Moogk, Robyn Yim, D. Michael Strong, Jonathan G. Drachman, Jo Anna Reems> ;Transfusion. 2004 Jan 1
13 citations
N-myc oncogene expression in neuroblastoma is driven by Sp1 and Sp3.
Matthew C. Tuthill, Randal K. Wada, Jason M Arimoto, Christine N Sugino, Kelli K. Kanemaru, Kenneth K. Takeuchi, Neil Sidell> ;Molecular Genetics and Metabolism. 2003 Sep 1
Targeting oncogene expression in a childhood cancer.
Matthew C. Tuthill, Randal K. Wada> ;Hawaii Medical Journal. 2003 Oct 1
9 citations
In vitro and in vivo effects of easily administered, low-toxic retinoid and phenylacetate compounds on human neuroblastoma cells
Neil Sidell, Marzia Pasquali, Srividya Malkapuram, Arun B. Barua, T. Wanichkul, Randal K. Wada> ;British Journal of Cancer. 2003 Jul 21
7 citations
Immunolocalization of a Na-K-2Cl cotransporter in human tracheobronchial smooth muscle.
Lynn M. Iwamoto, Kenneth T. Nakamura, Randal K. Wada> ;Journal of Applied Physiology. 2003 Apr 1
50 citations
Differentiation of Human Neuroblastoma by Phenylacetate Is Mediated by Peroxisome Proliferator-activated Receptor γ
ShouWei Han, Randal K. Wada, Neil Sidell> ;Cancer Research. 2001 May 15
67 citations
Novel Expression and Function of Peroxisome Proliferator-activated Receptor Gamma (PPARγ) in Human Neuroblastoma Cells
Shou Wei Han, Marianne E. Greene, Joseph Pitts, Randal K. Wada, Neil Sidell> ;Clinical Cancer Research. 2001 Jan 1
7 citations
Pharmacokinetics of chronically administered all-trans-retinoyl-β-glucuronide in mice
Neil Sidell, Sayan Sawatsri, Michael J. Connor, Arun B. Barua, James Allen Olson, Randal K. Wada> ;Biochimica Et Biophysica Acta. 2000 Oct 18
9 citations
Transcriptional Upregulation of Retinoic Acid Receptor β (RARβ) Expression by Phenylacetate in Human Neuroblastoma Cells
Neil Sidell, Bieshia Chang, Joyce Yamashiro, Randal K. Wada> ;Experimental Cell Research. 1998 Feb 25
Join now to see all

Grant Support

Regulation Of The N-MYC Oncogene In NeuroblastomaNational Institute Of Neurological Disorders And Stroke1996–2004
Regulation Of The N MYC Oncogene In NeuroblastomaNational Institute Of Neurological Disorders And Stroke1997–1998
Regulation Of The N-MYC Oncogene In NeuroblastomaNational Institute Of Neurological Disorders And Stroke1995–1996
N-MYC Oncogene Regulation In Human NeuroblastomaNational Institute Of Neurological Disorders And Stroke1993–1995

Hospital Affiliations

Kapiolani Medical Center for Women & ChildrenHonolulu, Hawaii

RandalK.WadaMD

Dr. Wada is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Grant Support

Hospital Affiliations

Viewing the full profile is available to verified healthcare professionals only.